Why Accurate Adverse Event Grading Matters in Early-Phase Oncology Studies
In early-phase oncology trials, the distinction between a grade 2 and grade 3 adverse event (AE) can have significant implications. In studies using model-assisted dose-finding designs, inaccurate grading can influence dose escalation, phase transitions, and the interpretation of critical safety data.
Ensuring grading accuracy is essential to protecting patients and supporting reliable study decisions. This infographic explores the potential consequences of AE misclassification and the targeted oversight measures that can help mitigate risk while preserving investigator judgment.
What’s Inside:
- The impact of grading decisions: How a single AE grade can influence dose escalation, phase transitions, safety interpretation, and trial direction.
- Considerations for early-phase oncology: Why grading accuracy is especially consequential in model-assisted dose-finding designs with predefined transition rules.
- Approaches to risk mitigation: How targeted source data verification, timely medical review, and site queries can help strengthen grading accuracy.
